|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Pliant Therapeutics, Inc. (PLRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,801,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Co.'s focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ss. Co.'s main product candidate, PLN-74809, is a dual selective inhibitor of avss6 and avss1 integrins that Co. is developing for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Co.'s second product candidate, PLN-1474, is a selective inhibitor of avss1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which Co. has partnered with Novartis Institutes for Biomedical Research, Inc.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
79,496 |
79,496 |
140,276 |
753,616 |
Total Sell Value |
$918,974 |
$918,974 |
$1,966,214 |
$18,268,658 |
Total People Sold |
5 |
5 |
5 |
5 |
Total Sell Transactions |
5 |
5 |
10 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ouimette Mike |
General Counsel & Corp. Secy |
|
2022-12-20 |
4 |
S |
$19.10 |
$90,144 |
D/D |
(4,719) |
8,875 |
|
- |
|
Hull Hans |
Chief Business Officer |
|
2022-12-20 |
4 |
S |
$19.10 |
$167,108 |
D/D |
(8,748) |
138,191 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
19,375 |
90,067 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,876 |
155,313 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
68,751 |
128,024 |
|
- |
|
Ouimette Mike |
General Counsel & Corp. Secy |
|
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
13,594 |
13,594 |
|
- |
|
Hull Hans |
Chief Business Officer |
|
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,578 |
146,939 |
|
- |
|
Tepper Robert I |
10% Owner |
|
2022-11-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
1,839,160 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2022-10-25 |
4 |
AS |
$25.05 |
$125,241 |
D/D |
(5,000) |
133,437 |
|
- |
|
Tepper Robert I |
10% Owner |
|
2022-09-20 |
4 |
AS |
$0.00 |
$0 |
D/D |
(2,000,000) |
3,839,160 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-09-12 |
4 |
AS |
$22.54 |
$281,851 |
D/D |
(12,502) |
59,273 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-09-12 |
4 |
OE |
$2.08 |
$26,004 |
D/D |
12,502 |
71,775 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-07-12 |
4 |
AS |
$22.50 |
$281,205 |
D/D |
(12,498) |
59,273 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-07-12 |
4 |
OE |
$2.08 |
$25,996 |
D/D |
12,498 |
71,771 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-07-11 |
4 |
AS |
$22.50 |
$337,500 |
D/D |
(15,000) |
59,273 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2022-07-11 |
4 |
OE |
$2.08 |
$31,200 |
D/D |
15,000 |
74,273 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2022-07-11 |
4 |
AS |
$20.00 |
$60,000 |
D/D |
(3,000) |
138,436 |
|
- |
|
Cummings Keith Lamont |
Chief Financial Officer |
|
2021-09-03 |
4 |
OE |
$2.08 |
$41,600 |
D/D |
20,000 |
67,621 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2021-06-18 |
4 |
AS |
$28.62 |
$360,821 |
D/D |
(12,500) |
137,080 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2021-06-14 |
4 |
AS |
$32.98 |
$132,102 |
I/I |
(4,000) |
449,317 |
|
- |
|
Hull Hans |
Chief Business Officer |
|
2021-05-26 |
4 |
OE |
$2.08 |
$9,360 |
D/D |
4,500 |
125,246 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2021-05-14 |
4 |
AS |
$28.53 |
$100,224 |
I/I |
(3,500) |
453,317 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2021-04-14 |
4 |
AS |
$30.33 |
$106,161 |
I/I |
(3,500) |
456,817 |
|
- |
|
Coulie Bernard |
President and CEO |
|
2021-04-13 |
4 |
OE |
$2.08 |
$12,480 |
D/D |
6,000 |
54,840 |
|
- |
|
Lefebvre Eric |
Chief Medical Officer |
|
2021-03-18 |
4 |
AS |
$39.38 |
$492,678 |
D/D |
(12,500) |
149,580 |
|
- |
|
133 Records found
|
|
Page 4 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|